Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Otoharmonics receives patent approval for Levo tinnitus system

Otoharmonics announces US patent approval for unique elements of their Levo tinnitus system.

Utilizing an FDA-cleared neuroscience-based approach, the Levo System offers a patented method to provide personalized sound therapy while sleeping.

"This is a significant advancement in tinnitus care," said Michael Baker, CEO and President of Otoharmonics. "Patent approval reinforces what we already know: The Levo System stands apart from every other tinnitus therapy on the market."

Unlike other tinnitus therapies, only the Levo System:

Is specifically designed for use during sleep

Has a patented sound matching method to identify a patient’s unique tinnitus sound

Offers the ability to hear what patients hear and develop truly personalized therapy

Can track patient use and response to therapy using a patented method leveraging smart technology

Exclusively integrates the Tinnitus Functional Index (TFI) to measure and monitor tinnitus impact on quality of life

Is FDA-cleared as a medical device using Apple hardware and proprietary software

Has high fidelity custom-fit ear buds

Otoharmonics is a privately held company with headquarters in Portland, Oregon USA. An international team of world-class neuroscientists, clinicians, business professionals and patients, Otoharmonics has developed the patented Levo System for the management of tinnitus symptoms.

With a personal approach and a deep understanding of the impact tinnitus can have, Levo is designed to be user-friendly and capable of delivering custom sound therapy based on the specific needs of the individual.